EUVIMEDEUVIMED entdecken
Crossref

Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers

David Toro-Tobon iD, John C Morris, Crystal Hilger, Candy Peskey, Jolanta M Durski, Mabel Ryder

Thyroid® · 2024-01 · 34 (1) · 70-81

DOI: 10.1089/thy.2023.0456 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thyroid®, online erschienen am 16.01.2024. Verfasst von David Toro-Tobon und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA. Hauptthemen laut MEDLINE: Thyroid Neoplasms, Iodine, Adenocarcinoma, Follicular. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Redifferentiation therapy (RDT) can restore radioactive iodine (RAI) uptake in differentiated thyroid cancer (DTC) cells to enable salvage 131 I therapy for previously RAI refractory (RAIR) disease. This study evaluated the clinical outcomes of patients who underwent RDT and identified clinicopathologic characteristics predictive of RAI restoration following RDT.

Methods

This is a retrospective case series of 33 patients with response evaluation criteria in solid tumors (RECIST)-progressive metastatic RAIR-DTC who underwent RDT between 2017 and 2022 at the Mayo Clinic (Rochester, MN). All patients underwent genomic profiling and received MEK, RET or ALK inhibitors alone, or combination BRAF -MEK inhibitors for 4 weeks. At week 3, those with increased RAI avidity in metastatic foci received high-dose 131 I therapy. Baseline and clinicopathologic outcomes were comprehensively reviewed.

Results

Of the 33 patients, 57.6% had restored RAI uptake following RDT (Redifferentiated subgroup). 42.1% (8/19) with papillary thyroid cancers (PTC), 100% (4/4) with invasive encapsulated follicular variant PTCs (IEFV-PTCs), and 100% (7/7) with follicular thyroid cancers (FTC) redifferentiated. All (11/11) RAS mutant tumors redifferentiated compared with 38.9% (7/18) with BRAF mutant disease (6 PTC and 1 IEFV-PTC). 76.5% (13/17) of redifferentiated and 66.7% (8/12) of non-redifferentiated patients achieved a best overall RECIST response of stable disease (SD) or non-complete response/non-progressive disease. Both subgroups had a median 12% tumor shrinkage at 3 weeks on drug(s) alone. The redifferentiated subgroup, following high-dose 131 I therapy, achieved an additional median 20% tumor reduction at 6 months after RDT. There were no statistically significant differences between both groups in progression free survival (PFS), time to initiation of systemic therapy, and time to any additional therapy. Of the entire cohort, 6.1% (2/33) experienced histologic transformation to anaplastic thyroid cancer, 15.1% (5/33) died, and all had redifferentiated following RDT and received 131 I therapy.

Conclusion

RDT has the potential to restore RAI avidity and induce RECIST responses following 131 I therapy in select patients with RAIR-DTC, particularly those with RAS -driven “follicular” phenotypes. In patients with PTC, none of the evaluated clinical outcomes differed statistically between the redifferentiated and non-redifferentiated subgroups. Further studies are needed to better characterize the long-term survival and/or safety outcomes of high-dose RAI following RDT, particularly whether it could be associated with histologic anaplastic transformation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Thyroid NeoplasmsIodineAdenocarcinoma, FollicularHumansIodine RadioisotopesRetrospective StudiesProto-Oncogene Proteins B-rafProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases

Stichwörter der Autor:innen

radioactive iodine therapyradioiodine redifferentation therapyradioiodine refractory thyroid cancersradioiodine uptakethyroid cancer

Substanzen

Iodine RadioisotopesIodineProto-Oncogene Proteins B-rafProtein Kinase InhibitorsMitogen-Activated Protein Kinase Kinases

Autor:innen und Institutionen

  • Division of Endocrinology, Diabetes, Metabolism, and Nutrition, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota, USA.
  • Division of Nuclear Medicine, Mayo Clinic, Rochester, Minnesota, USA.

ORCID-Profile: David Toro-Tobon

Zitieren

APA

Toro-Tobon, D., Morris, J. C., Hilger, C., Peskey, C., Durski, J. M., & Ryder, M. (2024). Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers. Thyroid®, 34(1), 70-81. https://doi.org/10.1089/thy.2023.0456

Vancouver

Toro-Tobon D, Morris JC, Hilger C, Peskey C, Durski JM, Ryder M. Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers. Thyroid®. 2024;34(1):70-81. doi:10.1089/thy.2023.0456

BibTeX
@article{ToroTobon2024,
  author = {Toro-Tobon, David and Morris, John C and Hilger, Crystal and Peskey, Candy and Durski, Jolanta M and Ryder, Mabel},
  title = {Clinical Outcomes of Radioactive Iodine Redifferentiation Therapy in Previously Iodine Refractory Differentiated Thyroid Cancers},
  journal = {Thyroid®},
  year = {2024},
  volume = {34},
  number = {1},
  pages = {70--81},
  doi = {10.1089/thy.2023.0456}
}
Kostenlos starten →